The toxin strychnine, the primary component of the traditional Chinese medicine, may act in the STAT3 pathway, investigators ...

A dry cough can be classified as acute or chronic, based on its duration ... through your mouth to see inside your airways).

The company is advancing multiple trials, including a human abuse potential trial, a Phase IIb study for chronic cough in idiopathic pulmonary fibrosis (IPF), and a Phase IIa trial for refractory ...

Analyst Faisal Khurshid from Leerink Partners reiterated a Buy rating on Trevi Therapeutics (TRVI – Research Report) and keeping the ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that it has completed enrollment in its Phase 2a trial for the ...

While she tried everything she could to keep her skin healthy—moisturizing regularly and drinking plenty of water—Elisha ...

With its lead product candidate, Haduvio, the company aims to treat chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). The Phase 2b CORAL trial for the ...

for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio ...

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic ...